Celebrating Innovation in Medical Aesthetics

Ottawa, Canada  — January 25, 2024 — Spiderwort, the biotech company transforming regenerative medicine, will attend the IMCAS World Congress next week in Paris, France from February 1-3, 2024. This year marks the 25th anniversary of the leading congress in dermatology, plastic surgery, and aging science. 

The IMCAS World Congress brings together top experts in medical aesthetics, offering an unparalleled platform for learning and collaboration. Spiderwort will showcase its pioneering cellulose-based approach to dermal filler injectables through its CelluJuve product initiative. CelluJuve has been developed with the intention to bring minimized adverse effects and greater longevity without compromising quality, control, or precision  for medical aesthetic professionals and their clients.

“Attending the IMCAS World Congress in its 25th year is a privilege and an exciting opportunity for Spiderwort to exchange knowledge and experiences with a truly global audience.” Dr. Charles M. Cuerrier, CEO and Co-Founder, “This event is a forum for next-generation innovations and breakthroughs. We are looking forward to building new partnerships aligned with our mission to advance the field of medical aesthetics,” 

This strategic trip follows closely behind Spiderwort’s recent announcement of its CelluJuve Clinical Advisory Board made up of renowned experts from the fields of plastic surgery and dermatology.

About Spiderwort
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort’s biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.

Media Contact

Shannon Murphy

Hear More From Us